Immuneering (IMRX) Registration Filing summary

Company overview and business model

• Clinical-stage oncology company focused on developing therapies for cancer using Deep Cyclic Inhibition (DCI) of core signaling pathways, particularly the MAPK pathway, to target cancer cells while sparing healthy cells.

• Lead product candidate, atebimetinib (IMM-1-104), is in Phase 1/2a trials for advanced solid tumors, including RAS or RAF mutations, and is designed as a once-daily oral MEK inhibitor.

• Proprietary informatics-based discovery and 3D tumor modeling platforms guide pipeline development and patient profiling.

• Pipeline includes additional programs targeting RAS, an undisclosed target, and other small molecule drug discovery efforts.

Financial performance and metrics

• As of June 30, 2025, net tangible book value was $20.8 million, or $0.58 per share, with 35,987,306 shares outstanding.

• After a $100 million offering at $3.25 per share, as adjusted net tangible book value would be $118.0 million, or $1.77 per share, resulting in immediate dilution of $1.48 per share to new investors.

• Financial statements for 2024 and 2023 audited by RSM US LLP, with a going concern explanatory paragraph.

Use of proceeds and capital allocation

• Net proceeds from offerings will be used to advance preclinical and clinical development of product candidates, for working capital, and general corporate purposes.

• Pending use, proceeds will be invested in short- and intermediate-term, interest-bearing obligations or U.S. government securities.